Amino Terminal Pro–B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background and Purpose—: Because of its association with atrial fibrillation and heart failure, we hypothesized that amino terminal pro–B-type natriuretic peptide (NT-proBNP) would identify a subgroup of patients from the Warfarin–Aspirin Recurrent Stroke Study, diagnosed with inferred noncardioembolic ischemic strokes, where anticoagulation would be more effective than antiplatelet agents in reducing risk of subsequent events. Methods—: NT-proBNP was measured in stored serum collected at baseline from participants enrolled in Warfarin–Aspirin Recurrent Stroke Study, a previously reported randomized trial. Relative effectiveness of warfarin and aspirin in preventing recurrent ischemic stroke or death over 2 years was compared based on NT-proBNP concentrations. Results—: About 95% of 1028 patients with assays had NT-proBNP below 750 pg/mL, and among them, no evidence for treatment effect modification was evident. For 49 patients with NT-proBNP >750 pg/mL, the 2-year rate of events per 100 person-years was 45.9 for the aspirin group and 16.6 for the warfarin group, whereas for 979 patients with NT-proBNP ≤750 pg/mL, rates were similar for both treatments. For those with NT-proBNP >750 pg/mL, the hazard ratio was 0.30 (95% confidence interval: 0.12–0.84; P =0.021) significantly favoring warfarin over aspirin. A formal test for interaction of NT-proBNP with treatment was significant ( P =0.01). Conclusions—: For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents. Clinical Trial Registration—: This trial was not registered because enrollment began before 2005.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011258 · Cited by 1,168
Self-citationAntiphospholipid Antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke
(2004) · JAMA · doi:10.1001/jama.291.5.576 · Cited by 478 · cited 1×
“In APASS, bloods were obtained from consenting WARSS participants at baseline before randomization and treatment.(23) We learned from APASS investigators that blood specimens remained from approximately 1000 participants.”
Hijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Ezekowitz, M. D., Hohnloser, S. H., Reilly, P. A., Vinereanu, D., Siegbahn, A., Yusuf, S., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.038729 · Cited by 402
Patton, K. K., Ellinor, P. T., Heckbert, S. R., Christenson, R. H., DeFilippi, C., Gottdiener, J. S., & Kronmal, R. A. (2009) · Circulation · doi:10.1161/circulationaha.109.873265 · Cited by 310 · cited 2×
“In the Cardiovascular Health Study, a large cohort study of elderly people followed for cardiovascular outcomes, the risk of developing incident atrial fibrillation was increased in those with elevated NT-proBNP, but not during the initial 2 years.(3) Follow-up in WARSS was a maximum of 2 years.”
Self-citation
Cited by
Katan, M., & Luft, A. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1649503 · Cited by 2,137
Stroke risk factors, genetics, and prevention
Boehme, A. K., Esenwa, C., & Elkind, M. S. V. (2017) · Circulation Research · doi:10.1161/circresaha.116.308398 · Cited by 1,952
“patients with evidence of elevations in N-terminal probrain natriuretic protein who are not known to have AF.(90) Further”
BackgroundSelf-citationEmbolic strokes of undetermined source: the case for a new clinical construct
Hart, R. G., Diener, H.-C., Coutts, S. B., Easton, J. D., Granger, C. B., O'Donnell, M. J., Sacco, R. L., & Connolly, S. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70310-7 · Cited by 1,681
Kamel, H., & Healey, J. S. (2017) · Circulation Research · doi:10.1161/circresaha.116.308407 · Cited by 417
Kamel, H., Longstreth, W., Tirschwell, D. L., Kronmal, R. A., Broderick, J. P., Palesch, Y. Y., Meinzer, C., Dillon, C., Ewing, I., Spilker, J. A., et al. (2019) · International Journal of Stroke · doi:10.1177/1747493018799981 · Cited by 380
Self-citation
Metadata
- Authors
- Longstreth, W. T., Kronmal, R. A., Thompson, J. L. P., Christenson, R. H., Levine, S. R., Gross, R., Brey, R. L., Buchsbaum, R., Elkind, M. S. V., Tirschwell, D. L., Seliger, S. L., Mohr, J. P., & deFilippi, C. R.
- Venue
- Stroke
- Published
- 2013-03
- Volume
- 44
- Issue
- 3
- Pages
- 714-719
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2155690271
- Cited by
- 111
- References
- 4
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.